AAN 2026 | Guidance for using blood-based biomarkers in AD: which test should be used and in which patients?

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses current clinical guidance on Alzheimer’s disease biomarker testing, emphasizing its use in cognitively impaired patients and the value of ptau217-based blood tests for accurate detection of pathology while avoiding unnecessary complexity from multiple biomarkers. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.